Clinical Trials Logo
  1. Home
  2. Erythropoietic Protoporphyria
  3. NCT03682731

Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria Clinical Trial

Official title:
Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria

Clinical Trial Summary

Background: Erythropoietic protoporphyria (EPP) is characterized by development of painful skin symptoms upon exposure to visible light dye to accumulation of the photoactive substance protoporphyrin IX (PpIX) in the skin.This study aimed to quantify the actual light exposure of patients with EPP during everyday life. The investigators further aimed to establish the associations between symptoms and light exposure, use of protective clothes, and erythrocyte PpIX concentration.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03682731
Study type Observational
Source Bispebjerg Hospital
Contact
Status Completed
Phase
Start date April 1, 2017
Completion date August 1, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00979745 - Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 3
Active, not recruiting NCT05308472 - Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP Phase 2
Completed NCT00004831 - Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria N/A
Completed NCT05572125 - Iron Therapy in Erythropoietic Protoporphyria
Completed NCT01605136 - Phase III Confirmatory Study in Erythropoietic Protoporphyria Phase 3
Completed NCT01422915 - Sorbent Therapy of the Cutaneous Porphyrias Phase 2/Phase 3
Completed NCT04053270 - Multicentre Phase III Erythropoietic Protoporphyria Study Phase 3
Completed NCT00004940 - Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria Phase 3
Recruiting NCT06388642 - Pharmacokinetics of Afamelanotide in EPP Patients Phase 1/Phase 2
Recruiting NCT05020184 - Effect of Oral Cimetidine in the Protoporphyrias Phase 2
Completed NCT01688895 - Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Completed NCT04578496 - A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP) Phase 3
Recruiting NCT00206869 - Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria N/A
Recruiting NCT05780840 - Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria N/A
Completed NCT02979249 - Oral Iron for Erythropoietic Protoporphyrias N/A
Enrolling by invitation NCT05883748 - Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP Phase 2/Phase 3
Completed NCT01097044 - Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) Phase 2